Search company, investor...

Verinata Health

Founded Year



Acquired | Acquired

Total Raised




About Verinata Health

Verinata Health, formerly Artemis Health, develops and offers non-invasive tests for early identification of fetal chromosomal abnormalities using proprietary technology. The company aims to reduce the anxiety associated with multi-step processes, false-positive rates, non-specified results of current prenatal screening methods, as well as the risk of invasive procedures. Verinata is conducting a prospective, blinded pivotal study to clinically validate the sensitivity and specificity of its first prenatal test on a large scale. In January 2013, Verinata Health was acquired by Illumina. The valuation of Verinata Health was $350 million. Other terms of the deal were not released.

Headquarters Location

1531 Industrial Road

San Carlos, California, 94070,

United States


Missing: Verinata Health's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Verinata Health's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Verinata Health

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Verinata Health in 1 CB Insights research brief, most recently on Jan 20, 2021.

Expert Collections containing Verinata Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Verinata Health is included in 1 Expert Collection, including Omics.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Verinata Health Patents

Verinata Health has filed 68 patents.

The 3 most popular patent topics include:

  • Genetics
  • Molecular biology
  • Chromosomal abnormalities
patents chart

Application Date

Grant Date


Related Topics




Genetics, Molecular biology, Transcription factors, Cytogenetics, Genomics


Application Date


Grant Date



Related Topics

Genetics, Molecular biology, Transcription factors, Cytogenetics, Genomics



Latest Verinata Health News

BioReference Labs Acquires US Ariosa Lab NIPT Business From Roche

Aug 17, 2021

Save for later NEW YORK – Opko subsidiary BioReference Laboratories announced on Monday that it has acquired the US Ariosa centralized lab prenatal testing business from Roche. Financial and other terms of the deal were not disclosed. Ariosa's noninvasive prenatal screening test, the Harmony Prenatal Test, has been performed in more than 1.5 million patients. The acquisition will complement BioReference's specialty health division GenPath, which currently offers the ClariTest Core. Both tests use the same core technology, BioReference said in a statement. "Acquiring the US Ariosa centralized laboratory prenatal testing business allows us to expand our [noninvasive prenatal screening] offerings and further underscores our commitment to prenatal screening," Jon Cohen, executive chairman of BioReference, said in a statement. In May, Ariosa and Illumina settled a long-running patent dispute across four cases over sequencing-related methods used in NIPT that began when Verinata Health  filed suit  against Ariosa in 2012. Verinata was then acquired by Illumina, which  sued  in 2014 and 2015 for patent infringement. Ariosa countersued for non-infringement, invalidity of the patents, breach of the covenant of good faith and fair dealing, and breach of contract. In 2018, a jury awarded Illumina  $26.7 million  in damages for the 2014 lawsuit, which the US Court of Appeals for the Federal Circuit affirmed in 2020.

Verinata Health Frequently Asked Questions (FAQ)

  • When was Verinata Health founded?

    Verinata Health was founded in 2001.

  • Where is Verinata Health's headquarters?

    Verinata Health's headquarters is located at 1531 Industrial Road, San Carlos.

  • What is Verinata Health's latest funding round?

    Verinata Health's latest funding round is Acquired.

  • How much did Verinata Health raise?

    Verinata Health raised a total of $76.57M.

  • Who are the investors of Verinata Health?

    Investors of Verinata Health include Illumina, Sutter Hill Ventures, Mohr Davidow Ventures, Alloy Ventures, Qualifying Therapeutic Discovery Project and 4 more.

  • Who are Verinata Health's competitors?

    Competitors of Verinata Health include Ariosa Diagnostics and 2 more.

Compare Verinata Health to Competitors

Ravgen Logo

Ravgen specializes in prenatal diagnostic testing. The company has developed and patented a variety of noninvasive prenatal tests that simply require a safe blood draw from the mother. Currently, the focus for Ravgen's core technology is on testing for single-gene disorders, such as cystic fibrosis, sickle cell anemia, and the Jewish panel, as well as paternity testing.

Sequenom Logo

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT, HerediT UNIVERSAL, MaterniT GENOME, MaterniT 21 PLUS, NextView, SensiGene and VisibiliT, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists.

Ariosa Diagnostics

Ariosa Diagnostics, formerly Tandem Diagnostics and Aria Diagnostics, is a molecular diagnostics company providing prenatal tests for maternal and fetal health. Ariosa is using its technology to perform a directed analysis of cell-free DNA in blood. The company's blood test equips pregnant women and healthcare providers with reliable information to make decisions regarding health. On August 16th, 2021, Ariosa Diagnostics was acquired by Bio-Reference Laboratories. The terms of the transaction were not disclosed.

Natera Logo

Natera is a diagnostics company that develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity, Vistara, a single-gene mutations screening test to identify single-gene disorder, Horizon carrier screening to determine carrier status for various genetic diseases, and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage, and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests, Signatera, a circulating tumor DNA technology that screens for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company was formerly known as Gene Security Network and changed its name to Natera in 2012. The company was founded in 2004 and is based in Austin, Texas.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.